While the present study provided encouraging data, we are conducting an additional phase II study (SPIRAL-0) to confirm the safety and efficacy of osimertinib in ≥75-year-old patients with untreated NSCLC harboring EGFR-activating mutations [36]. Here, EGFR is linked to non-small cell lung carcinoma.